17.12.2015   

EN

Official Journal of the European Union

C 421/26

1.

On 9 December 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Astorg Asset Management Sàrl. acting on behalf of Astorg VI (‘Astorg’, Luxembourg) and The Goldman Sachs Group, Inc. (‘Goldman Sachs’, United States) acquire within the meaning of Article 3(1)(b) of the Merger Regulation control over Laboratoire HRA Pharma SAS and its subsidiaries (‘HRA Pharma’, France), by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7887 — Goldman Sachs/Astorg Asset Management/HRA Pharma, to the following address: